PDE3B
PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Overview
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.75, animal model 0.36, genetic association 0.16, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
- 1 · What it is
PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
- 2 · What goes wrong in cancer
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process.
- 3 · How drugs use it
No product in this corpus aims at PDE3B yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:8779 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13370 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000152270 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.58, essential thrombocythemia 0.58 (GraphQL API, CC0))
Biology
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes. Location: Membrane (UniProt). Locus 11p15.2 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.58 with myeloproliferative neoplasm (MONDO_0020076)
- Essential thrombocythaemia: Open Targets association 0.58 with essential thrombocythemia (MONDO_0005029)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PDE3B" OR ABSTRACT:"PDE3B" OR TITLE:"phosphodiesterase 3B" OR ABSTRACT:"phosphodiesterase 3B" OR TITLE:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B" OR ABSTRACT:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B" OR TITLE:"HcGIP1" OR ABSTRACT:"HcGIP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDE3B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPDE3A
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetCALR
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetRPS29
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TermErythromelalgia
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetRTEL1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetSBDS
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetETNK1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).